TY - JOUR
T1 - Characterization of human papillomavirus antibodies in individuals with head and neck cancer
AU - Lang Kuhs, Krystle A.
AU - Pawlita, Michael
AU - Gibson, Sandra P.
AU - Schmitt, Nicole C.
AU - Trivedi, Sumita
AU - Argiris, Athanassios
AU - Kreimer, Aimée R.
AU - Ferris, Robert L.
AU - Waterboer, Tim
N1 - Publisher Copyright:
© 2016 Elsevier Ltd.
PY - 2016/6/1
Y1 - 2016/6/1
N2 - Background: Human papillomavirus type 16 (HPV16) E6 antibodies are a promising biomarker of oropharyngeal cancer (OPC); however, seropositivity among non-OPC cases is not well characterized. Methods: Pre-treatment sera from 260 (38 OPC, 222 non-OPC) incident head and neck cancers diagnosed at the University of Pittsburgh between 2003 and 2006 were tested for HPV16 (L1,E1,E2,E4,E6,E7) and non-HPV16 E6 (HPV6,11,18,33) antibodies. Sensitivity and specificity of HPV16 E6 antibodies for HPV-driven tumors was evaluated among tumors with known HPV status (n = 25). Results: 63.2% of OPC versus 27.5% of non-OPC cases were HPV16 seropositive; HPV16 E6 seroprevalence was 60.5% and 6.3% respectively, odds ratio 22.8 (95% confidence interval [CI] 9.8-53.1). Sensitivity and specificity of HPV16 E6 antibodies for HPV-driven OPC was 100% [95% CI: 50-100%; n = 6] and 100% [95% CI: 60-100%, n = 4] compared to 0% (n = 2) and 0% (n = 13) for non-OPC cases. Conclusions: HPV16 antibodies were significantly more common in OPC versus non-OPC cases, particularly HPV16 E6 antibodies.
AB - Background: Human papillomavirus type 16 (HPV16) E6 antibodies are a promising biomarker of oropharyngeal cancer (OPC); however, seropositivity among non-OPC cases is not well characterized. Methods: Pre-treatment sera from 260 (38 OPC, 222 non-OPC) incident head and neck cancers diagnosed at the University of Pittsburgh between 2003 and 2006 were tested for HPV16 (L1,E1,E2,E4,E6,E7) and non-HPV16 E6 (HPV6,11,18,33) antibodies. Sensitivity and specificity of HPV16 E6 antibodies for HPV-driven tumors was evaluated among tumors with known HPV status (n = 25). Results: 63.2% of OPC versus 27.5% of non-OPC cases were HPV16 seropositive; HPV16 E6 seroprevalence was 60.5% and 6.3% respectively, odds ratio 22.8 (95% confidence interval [CI] 9.8-53.1). Sensitivity and specificity of HPV16 E6 antibodies for HPV-driven OPC was 100% [95% CI: 50-100%; n = 6] and 100% [95% CI: 60-100%, n = 4] compared to 0% (n = 2) and 0% (n = 13) for non-OPC cases. Conclusions: HPV16 antibodies were significantly more common in OPC versus non-OPC cases, particularly HPV16 E6 antibodies.
KW - HPV antibodies
KW - HPV seropositivity
KW - HPV16
KW - HPV16 E6
KW - Human papillomavirus 16
KW - Non-OPC
KW - Non-oropharyngeal cancer
KW - OPC
KW - Oropharyngeal cancer
UR - http://www.scopus.com/inward/record.url?scp=84961786714&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84961786714&partnerID=8YFLogxK
U2 - 10.1016/j.canep.2016.03.003
DO - 10.1016/j.canep.2016.03.003
M3 - Article
C2 - 27010729
AN - SCOPUS:84961786714
SN - 1877-7821
VL - 42
SP - 46
EP - 52
JO - Cancer Epidemiology
JF - Cancer Epidemiology
ER -
